News | Catheters | April 03, 2024

FDA Announces Teleflex and Arrow International Recall of ARROW QuickFlash Radial Artery and Radial Artery/Arterial Line Catheterization Kits for Increased Resistance That May Lead to Vessel Injuries, Narrowing, or Blockage

 

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries, serious health consequences, or death

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries, serious health consequences, or death

April 3, 2024 — The U.S. Food and Drug Administration (FDA) announced that Teleflex and Arrow International are recalling the ARROW QuickFlash Radial Artery and Radial Artery/Arterial Line Catheterization Kits after receiving reports of increased resistance in the guidewire handle and chamber during use. This issue may cause serious injury, including injury to blood vessel walls, narrowing of the blood vessels (vasospasm), artery blockage (embolism), or death.

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries, serious health consequences, or death.

Recalled Product 

  • Product Name: ARROW QuickFlash Radial Artery and Radial Artery/Arterial Line Catheterization Kits
  • Product Codes: See Recall Database Entry 
  • Devices Recalled in the U.S.: 334,995 
  • Dates Distributed: December 1, 2021 to January 27, 2024
  • Date Initiated by Firm: February 12, 2024

Device Use

The ARROW QuickFlash Radial Artery and Radial Artery/Arterial Line Catheterization Kits allow health care providers access to a patient’s peripheral arterial circulation or other small vessels. 

Reason for Recall  

Teleflex, and their subsidiary Arrow International, are recalling the ARROW QuickFlash Radial Artery and Radial Artery/Arterial Line Catheterization Kits after receiving reports of increased resistance in the guidewire handle and chamber during use. 

This issue may cause serious injury, including injury to blood vessel walls, narrowing of the blood vessels (vasospasm), artery blockage (embolism), or death. 
 
Teleflex/Arrow International reports 194 complaints. A total of 10 injuries, and one death have been reported related to this issue. 

Who May Be Affected 

  • People who receive care with the ARROW QuickFlash Radial Artery and Radial Artery/Arterial Line Catheterization Kits.

What to Do 

On February 12, 2024, Teleflex and Arrow International sent an Urgent Medical Device Recall letter to customers that included the following recommended actions:

For Medical Facilities

  • Immediately:
    • Check inventory for product within the scope of this recall. 
    • Stop using and distributing affected product.
    • Quarantine affected product.
  • Mark the applicable checkbox (affected product or no affected product) on the acknowledgement form included with the letter. Fax the form to 1-855-419-8507 to Attn: Customer Service or email the form to [email protected]
    • If you have affected product, a customer service representative will contact you with a Return Goods Authorization (RGA) number and will provide instructions for the return of affected products to Teleflex. Teleflex (or the local dealer) will issue a credit note upon receipt of the returned affected product.
    • Ensure you only list batch numbers in scope of the recall notice when completing the form. 

For Distributors

  • Provide a copy of the Urgent Medical Device Recall letter to all customers who have received impacted product. Each customer must complete the acknowledgement form and return it to the distributor. 
  • Immediately:
    • Check inventory for product within the scope of this recall. 
    • Stop using and distributing affected product.
    • Quarantine affected product.
    • Return all product in scope.
  • Confirm to Teleflex that field activities outlined have been completed. 
  • After completing actions, forward the completed acknowledgement form to [email protected].
    • Ensure you only list batch numbers in scope of the recall notice when completing the form. 
  • If product was distributed outside of the country, notify Teleflex Customer Service.

Contact Information 

Customers with questions should contact Teleflex and Arrow International Customer Service: 
Phone: 1-866-396-2111
FAX: 1-855-419-8507
Email: [email protected] 

Additional Resources 

How do I report a problem?

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX.


Related Content

News | FDA

Jan. 13, 2026 – Innovative Health, Inc. has received its 50th clearance from FDA to reprocess single-use medical devices ...

Home January 15, 2026
Home
News | FDA

Jan. 12, 2026 — HeartLung Corp. has announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD, its AI ...

Home January 12, 2026
Home
News | FDA

Jan. 6, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the FDA approval of the Gore Viabahn ...

Home January 06, 2026
Home
News | FDA

Dec. 22, 2025 — Abbott recently announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt ...

Home January 05, 2026
Home
News | FDA

Dec. 18, 2025 — Huxley Medical has announced the SANSA home sleep apnea test has received regulatory clearance from the ...

Home December 19, 2025
Home
News | FDA

Dec. 18, 2025 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer ...

Home December 18, 2025
Home
News | FDA

Dec. 15, 2025 — HeartSciences Inc., a healthcare information technology company advancing the use of ECG/EKGs through ...

Home December 16, 2025
Home
News | FDA

Nov. 25, 2025 — Remington Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance and announced ...

Home December 09, 2025
Home
News | FDA

Dec. 3, 2025 — Atraverse Medical, a medical device company developing next-generation left-heart access technology, has ...

Home December 05, 2025
Home
News | FDA

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA ...

Home December 01, 2025
Home
Subscribe Now